Protocol No.: S1803

Title
Phase III Study of Daratumumab/rHuPH20 (NSC-810304) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Principal Investigator
Veltri, Lauren
Phase
III
Age Group
Adult
Applicable Disease Site
Multiple Myeloma
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Sylvia McEwuen, RN, CCRC
Study Coordinator/Research Nurse
Phone: +1 304-293-1683

View on ClinicalTrials.gov